<html>
<head>
<title>Section 318:16-c Commission to Study the Standards for Collaborative Pharmacy Practice. </title>
<!-- Hide metadata
<titlename>TITLE XXX OCCUPATIONS AND PROFESSIONS</titlename>
<chapter>CHAPTER 318 PHARMACISTS AND PHARMACIES</chapter>
<sectiontitle>Section 318:16-c Commission to Study the Standards for Collaborative Pharmacy Practice. </sectiontitle>
-->
<meta name="titlename" content="TITLE XXX OCCUPATIONS AND PROFESSIONS">
<meta name="chapter" content="CHAPTER 318 PHARMACISTS AND PHARMACIES">
<meta name="sectiontitle" content="Section 318:16-c Commission to Study the Standards for Collaborative Pharmacy Practice. ">
<meta name="sourcenote" content="Source.  2015, 190:2, eff. July 6, 2015.">
<meta name="codesect" content="<br>&nbsp&nbsp&nbspThere is established a commission to study the standards for collaborative pharmacy practice.<br>&nbsp&nbsp&nbspI. The members of the commission shall be as follows:<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(a) One member of the senate, appointed by the president of the senate.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(b) Three members of the house of representatives, appointed by the speaker of the house of representatives, 2 of whom shall be members of the health, human services and elderly affairs committee and one of whom shall be a member of the executive departments and administration committee.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(c) A representative of the New Hampshire Society of Health-System Pharmacists, appointed by the society.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(d) A representative of the New Hampshire Pharmacists Association, appointed by the association.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(e) A representative of the New Hampshire board of pharmacy, appointed by the board.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(f) A representative from the Coalition of New Hampshire Chain Drug Stores, appointed by the coalition.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(g) A representative from the New Hampshire Independent Pharmacy Association, appointed by the association.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(h) A provider from a healthcare facility that is currently participating in a collaborative practice agreement approved by the board of pharmacy, appointed by the board.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(i) A pharmacist from a healthcare facility that is currently participating in a collaborative practice agreement approved by the board of pharmacy, appointed by the board.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(j) A representative from the New Hampshire Hospital Association, appointed by the association.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(k) A representative of the New Hampshire Medical Society, appointed by the society.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(l) A representative of the board of nursing, appointed by the board.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(m) A representative of the New Hampshire Nurse Practitioners Association, appointed by the association.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(n) A member who is a family physician, appointed by the board of medicine.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(o) A member who is an internist, appointed by the board of medicine.<br>&nbsp&nbsp&nbspII. Legislative members of the commission shall receive mileage at the legislative rate when attending to the duties of the commission.<br>&nbsp&nbsp&nbspIII. The commission's study shall include, but not be limited to:<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(a) Reviewing RSA 318:16-a and discussing areas where it is working effectively and where there are areas for improvement in the current framework of regulatory oversight;<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(b) Studying the national standards for best practice of collaborative practice;<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(c) Defining the appropriate training required for a pharmacist to engage in different scopes of practice;<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(d) Discussing how to expand access to collaborative practice pharmacy services to New Hampshire citizens in order to provide greater access to cost-effective care;<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(e) Defining collaborative pharmacy practice environments to ensure safety;<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(f) Identifying recommended solutions, both legislative and non-legislative;  and<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(g) Reviewing any other matter the committee deems relevant to its objective.<br>&nbsp&nbsp&nbspIV. The members of the commission shall elect a chairperson from among the members.  The first meeting of the commission shall be called by the first-named house member.  The first meeting of the commission shall be held within 30 days of the effective date of this section.  Five members of the commission shall constitute a quorum.<br>&nbsp&nbsp&nbspV. The commission shall report its findings and any recommendations for proposed legislation to the speaker of the house of representatives, the president of the senate, the house clerk, the senate clerk, the governor, and the state library on or before November 1, 2015.">
</head>
<body>
<center><h1>TITLE XXX<br>OCCUPATIONS AND PROFESSIONS</h1></center>
<center><h2>CHAPTER 318<br>PHARMACISTS AND PHARMACIES</h2></center>
<center><h2>Licensed Pharmacists</h2></center>
<center><h3>Section 318:16-c</h3></center>
<br><center>[RSA 318:16-c repealed by 2015, 190:3, effective November 2, 2015.]</center>
&nbsp;&nbsp;&nbsp;<b> 318:16-c Commission to Study the Standards for Collaborative Pharmacy Practice.  &#150;</b>
<codesect>
<br>
&nbsp&nbsp&nbsp
There is established a commission to study the standards for collaborative pharmacy practice.
<br>
&nbsp&nbsp&nbsp
I. The members of the commission shall be as follows:
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(a) One member of the senate, appointed by the president of the senate.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(b) Three members of the house of representatives, appointed by the speaker of the house of representatives, 2 of whom shall be members of the health, human services and elderly affairs committee and one of whom shall be a member of the executive departments and administration committee.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(c) A representative of the New Hampshire Society of Health-System Pharmacists, appointed by the society.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(d) A representative of the New Hampshire Pharmacists Association, appointed by the association.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(e) A representative of the New Hampshire board of pharmacy, appointed by the board.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(f) A representative from the Coalition of New Hampshire Chain Drug Stores, appointed by the coalition.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(g) A representative from the New Hampshire Independent Pharmacy Association, appointed by the association.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(h) A provider from a healthcare facility that is currently participating in a collaborative practice agreement approved by the board of pharmacy, appointed by the board.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(i) A pharmacist from a healthcare facility that is currently participating in a collaborative practice agreement approved by the board of pharmacy, appointed by the board.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(j) A representative from the New Hampshire Hospital Association, appointed by the association.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(k) A representative of the New Hampshire Medical Society, appointed by the society.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(l) A representative of the board of nursing, appointed by the board.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(m) A representative of the New Hampshire Nurse Practitioners Association, appointed by the association.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(n) A member who is a family physician, appointed by the board of medicine.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(o) A member who is an internist, appointed by the board of medicine.
<br>
&nbsp&nbsp&nbsp
II. Legislative members of the commission shall receive mileage at the legislative rate when attending to the duties of the commission.
<br>
&nbsp&nbsp&nbsp
III. The commission's study shall include, but not be limited to:
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(a) Reviewing RSA 318:16-a and discussing areas where it is working effectively and where there are areas for improvement in the current framework of regulatory oversight;
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(b) Studying the national standards for best practice of collaborative practice;
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(c) Defining the appropriate training required for a pharmacist to engage in different scopes of practice;
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(d) Discussing how to expand access to collaborative practice pharmacy services to New Hampshire citizens in order to provide greater access to cost-effective care;
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(e) Defining collaborative pharmacy practice environments to ensure safety;
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(f) Identifying recommended solutions, both legislative and non-legislative;  and
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(g) Reviewing any other matter the committee deems relevant to its objective.
<br>
&nbsp&nbsp&nbsp
IV. The members of the commission shall elect a chairperson from among the members.  The first meeting of the commission shall be called by the first-named house member.  The first meeting of the commission shall be held within 30 days of the effective date of this section.  Five members of the commission shall constitute a quorum.
<br>
&nbsp&nbsp&nbsp
V. The commission shall report its findings and any recommendations for proposed legislation to the speaker of the house of representatives, the president of the senate, the house clerk, the senate clerk, the governor, and the state library on or before November 1, 2015.
</codesect>
<sourcenote>
<p><b>Source.</b>  2015, 190:2, eff. July 6, 2015.</p>
</sourcenote>
</body>
</html>
